Silicon Valley Tax Directors Group

Home
Hot Topics
Member Index
Correspondence
Position Papers
Worldwide Totals
Statement of Purpose
Employment
Member’s Login



Members
Missing Image

 

Jeffrey A. Levenstam

BS Accountancy University of Illinois at Urbana-Champaign; CPA, California

Vice President, Tax

Theravance Biopharma US, Inc.

901 Gateway Boulevard

San Francisco, California 94080

Contact

650.808.3716 OFFICE PHONE

707.477.9953 MOBILE PHONE

jlevenstam@theravance.com

Professional Organizations

Silicon Valley Chapter of Tax Executives Institute; AICPA, CA Society of CPAs

Background

Big 4 international tax services partner; in-house responsibilities now include global income tax, indirect tax and property tax

Company Profile

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. Its product candidates include Revefenacin (TD-4208), an investigational long acting muscarinic antagonist, which is in Phase III clinical study for the treatment of chronic obstructive pulmonary disease; neprilysin (NEP) inhibitor program that is in Phase I clinical study to develop selective NEP inhibitors for the treatment of cardiovascular and renal diseases; and GI-targeted pan-Janus kinanse inhibitor program, which is in Phase I clinical study for inflammatory intestinal diseases. The company’s product candidates also comprise Axelopran, an investigational, once-daily, and oral peripherally active mu opioid receptor antagonist that is in Phase I!

I clinical trial for opioid induced constipation; Velusetrag, an oral and investigational medicine, which is in Phase II study for gastrointestinal motility disorders; and TD-6450, an internally discovered multivalent NS5A inhibitor that is in Phase II study. In addition, it focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol; the Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. was incorporated in 2013 under the laws of the Cayman Islands and is resident in Ireland.